Baseline characteristics of elderly patients with AML treated with chemotherapy or epigenetic therapy
| Characteristic . | Chemotherapy . | Azacitidine . | Decitabine . | 3-way P value . | Epigenetic . | Chemotherapy vs epigenetic P value . |
|---|---|---|---|---|---|---|
| Patients, n (%) | 557 (83) | 47 (7) | 67 (10) | 114 (17) | ||
| Male sex, n (%) | 358 (64) | 34 (72) | 44 (66) | .53 | 78 (68) | .4 |
| Median age, y (range) | 71 (65-89) | 74 (65-84) | 73 (65-86) | .1 | 74 (65-86) | .033 |
| ECOG performance status 0-2, n (%) | 527 (95) | 41 (87) | 67 (100) | .012‡ | 108 (95) | .9 |
| Median WBC count, × 109/L (range) | 5.8 (0.4-433) | 8.1 (0.7-79.1) | 2.8 (1.0-56.4) | .01 | 4.6 (0.7-79.1) | .12 |
| Median hemoglobin, g/dL (range) | 8.3 (3.8-14.2) | 8.4 (4.5-11.9) | 8.8 (4.0-14.6) | .01 | 8.7 (4-14.6) | .01 |
| Platelets, × 109/L | 51 (3-787) | 49 (2-437) | 58 (3-470) | .37 | 55 (2-470) | .23 |
| Median BM, % (range) | 43 (0-98) | 42 (1-85) | 32 (6-87) | .001 | 36 (1-87) | .002 |
| Median PB blasts, % (range) | 15 (0-99) | 5 (0-89) | 7 (0-69) | .001 | 7 (0-89) | .003 |
| Cytogenetics, n (%) | ||||||
| −5 or −7 alone | 15 (3) | 2 (4) | 0 (0) | .85* | 2 (2) | .74 |
| −5 or −7 with other abnormalities | 127 (23) | 10 (21) | 19 (28) | 29 (25) | ||
| Complex (≥ 3 abnormalities) | 42 (8) | 3 (6) | 4 (6) | 7 (6) | ||
| Noncomplex (≤ 2 abnormalities) | 98 (18) | 11 (23) | 13 (19) | 24 (21) | ||
| 11q23 | 14 (3) | 1 (2) | 0 (0) | 1 (1) | ||
| Diploid | 238 (43) | 19 (40) | 27 (40) | 46 (40) | ||
| Not done/insufficient metaphases* | 23 (4) | 1 (2) | 4 (6) | 5 (4) | ||
| FLT3-ITD, n (%) | 47 (8) | 4 (9) | 7 (10) | .85 | 11 (10) | .67 |
| NPM1 mutation, n (%)† | 23 (16) | 3 (13) | 0 (0) | .32 | 3 (9) | .26 |
| Characteristic . | Chemotherapy . | Azacitidine . | Decitabine . | 3-way P value . | Epigenetic . | Chemotherapy vs epigenetic P value . |
|---|---|---|---|---|---|---|
| Patients, n (%) | 557 (83) | 47 (7) | 67 (10) | 114 (17) | ||
| Male sex, n (%) | 358 (64) | 34 (72) | 44 (66) | .53 | 78 (68) | .4 |
| Median age, y (range) | 71 (65-89) | 74 (65-84) | 73 (65-86) | .1 | 74 (65-86) | .033 |
| ECOG performance status 0-2, n (%) | 527 (95) | 41 (87) | 67 (100) | .012‡ | 108 (95) | .9 |
| Median WBC count, × 109/L (range) | 5.8 (0.4-433) | 8.1 (0.7-79.1) | 2.8 (1.0-56.4) | .01 | 4.6 (0.7-79.1) | .12 |
| Median hemoglobin, g/dL (range) | 8.3 (3.8-14.2) | 8.4 (4.5-11.9) | 8.8 (4.0-14.6) | .01 | 8.7 (4-14.6) | .01 |
| Platelets, × 109/L | 51 (3-787) | 49 (2-437) | 58 (3-470) | .37 | 55 (2-470) | .23 |
| Median BM, % (range) | 43 (0-98) | 42 (1-85) | 32 (6-87) | .001 | 36 (1-87) | .002 |
| Median PB blasts, % (range) | 15 (0-99) | 5 (0-89) | 7 (0-69) | .001 | 7 (0-89) | .003 |
| Cytogenetics, n (%) | ||||||
| −5 or −7 alone | 15 (3) | 2 (4) | 0 (0) | .85* | 2 (2) | .74 |
| −5 or −7 with other abnormalities | 127 (23) | 10 (21) | 19 (28) | 29 (25) | ||
| Complex (≥ 3 abnormalities) | 42 (8) | 3 (6) | 4 (6) | 7 (6) | ||
| Noncomplex (≤ 2 abnormalities) | 98 (18) | 11 (23) | 13 (19) | 24 (21) | ||
| 11q23 | 14 (3) | 1 (2) | 0 (0) | 1 (1) | ||
| Diploid | 238 (43) | 19 (40) | 27 (40) | 46 (40) | ||
| Not done/insufficient metaphases* | 23 (4) | 1 (2) | 4 (6) | 5 (4) | ||
| FLT3-ITD, n (%) | 47 (8) | 4 (9) | 7 (10) | .85 | 11 (10) | .67 |
| NPM1 mutation, n (%)† | 23 (16) | 3 (13) | 0 (0) | .32 | 3 (9) | .26 |